Free shipping on all orders over $ 500

ML385

Cat. No. M8692
ML385 Structure
Synonym:

ML-385

Size Price Availability Quantity
Free Sample (0.5-1 mg)  USD 0 In stock
10mM*1mL in DMSO USD 55  USD55 In stock
5mg USD 50  USD50 In stock
10mg USD 85  USD85 In stock
25mg USD 170  USD170 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

ML385 inihbits the activity of the Nrf2 transcription factor by binding to Neh1, a NC-bZIP domain that allows Nrf2 to heterodimerize with small Maf proteins, blocking NRF2 transcriptional activity. Much research has been done on activating Nrf2 because it induces cytoprotective antioxidant genes. However, some cancer cells may use Nrf2 similarly for their survival. Nrf2 is overexpressed in certain cancers such as non-small cell lung cancer (NSCLC) often due to loss of function mutations in KEAP1, which targets Nrf2 for proteasomal degradation. ML385 was found to have anti-tumor activity with specificity and selectivity for NSCLC cells with KEAP1 mutations.

Product Citations
Customer Product Validations & Biological Datas
Source Front Oncol (2021). Figure 4. ML-385 (Abmole Bioscience, Houston, TX, USA)
Method Cell Migration and Cell Invasion Assays
Cell Lines Murine BC cell line 4T1 cells
Concentrations 0, 5, 10 µM
Incubation Time -
Results We found that ML-385 treatment significantly attenuated NRF2, p-NRF2 expression (Figure 4A) and NRF2-responsive gene levels (Figure 4B) in DPP-4i-treated BC cells. Notably, DPP-4i-driven BC cell migration and invasion were significantly abrogated by ML-385 treatment with a dose-dependent manner (Figures 4C, D). Furthermore, DPP-4i–driven metastasis-associated gene levels were significantly attenuated after ML-385 treatment in BC cells (Figure 4E). These data indicate that NRF2 inhibition reverses DPP-4i–driven BC metastases in vitro.
Chemical Information
Molecular Weight 511.59
Formula C29H25N3O4S
CAS Number 846557-71-9
Solubility (25°C) DMSO ≥ 30 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Anju Singh, et al. ACS Chem Biol. Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors

Related Keap1-Nrf2 Products
TAT-14

TAT-14 is a 14-mer peptide that acts as Nrf2 activator with an anti-inflammatory effect.

[D-Asp3]-Microcystin-LR

Microcystin-[D-Asp3]-LR/Microcystin A is a cyanotoxin.

Keap1-Nrf2 probe

Keap1-Nrf2 probe is a fluorescent Keap1-Nrf2 probe.

BAY-3605349

BAY-3605349 is an orally active Kelch-like ECH-associated protein 1 (KEAP1) activator as well as Nrf2 inhibitor for tumor-related studies.

Nrf2/HO-1 activator 1

Nrf2/HO-1 activator 1 is a potent Nrf2/HO-1 activator, neuroprotective agent.

  Catalog
Abmole Inhibitor Catalog




Keywords: ML385, ML-385 supplier, Keap1-Nrf2, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.